Activated variants of the c-abl protooncogene code for proteins that transform a wide range of hematopoietic cells as well as other cell types. v-abl, the gene transduced by Abelson murine leukemia virus (A-MuLV), originated in a lymphoid tumor (1) . The v-abl gene product is a 160-kDa tyrosine kinase (p160) whose N-terminal domain consists of MuLV core protein (gag) sequences; its 1003 C-terminal amino acids are homologous to c-abl (2) . Under commonly used infection conditions, v-abl readily transforms B-lymphoid cells. The disease caused by intraperitoneal injection of susceptible newborn mice is characterized by a short latent period (1-3 mo), paraspinous masses of lymphoid cells, and a distinctive cranial involvement ("caput medusa"). v-abl can also transform fibroblasts, pre-B cells, T cells, mast cells, macrophages, and erythroid cells, but these lineages are not commonly involved in vivo (3) . More recently, Kelliher et al. (4) and Chung et al. (5) have suggested that v-abl can cause a disease reminiscent of chronic myelogenous leukemia (CML).
In humans, the t(9;22) translocation giving rise to the Philadelphia chromosome appends 5' exons from an unrelated cellular gene, bcr, to the second exon of c-abl and gives rise to a fusion gene, bcr-abl. Production of the corresponding chimeric abl protein (p210 or p190) results in the leukemias of mature granulocytes (CML) or lymphoid series cells (Philadelphia chromosome-positive acute lymphocytic leukemia, ALL) (for review, see ref. 6 ). Several studies have attempted to recapitulate CML-like disease in a murine model system by retroviral transduction of the bcr-abl gene (4, 7, 8) . The malignancies induced by these protocols have varied somewhat, but a wide range of hematopoietic cell types are typically involved. Central features ofthe CML-like syndrome observed by Daley et al. (8) included massive splenic enlargement secondary to infiltration with mature granulocytes, a marked peripheral blood leukocytosis, and the presence of a bcr-abl provirus in the granulocytes of diseased animals. This syndrome is different from the malignancies of monocytic cells described by Kelliher et al. (4) ; these most closely resemble human histiocytic lymphomas not typically associated with the Philadelphia chromosome. More distinct still are the tumors of macrophage and erythroid derivation characterized by Elefanty et al. (7) .
To compare the abilities of v-abl and bcr-abl to cause CML-like disease, we placed the gene in the vector described by Daley et al. (8) , created a virus stock of high titer through use ofhelper virus, and employed the same infection protocol as in the previous study. We show here that v-abl induces a range of malignancies similar, but not identical, to those caused by bcr-abl.
MATERIALS AND METHODS Viral Stocks and Infections. A 4.7-kilobase (kb) BamHI fragment containing the v-abl sequence coding for p160 protein was subcloned into the pGD vector. The 5' long terminal repeat of this vector is derived from Moloney MuLV; the 3' long terminal repeat is a composite of the myeloproliferative sarcoma virus promoter and MuLV enhancer (8) . The B2 mutation (9) and internally promoted neo markers are as described (8) . The Hybridization and Protein Studies. DNA was prepared from peripheral blood granulocytes, liver, spleen, nodes, and tumor masses per standard protocols. After digestion with specified enzymes, DNAs were blotted to nylon membranes. Cytoplasmic RNAs were also obtained from cell lines, electrophoresed, and blotted by standard techniques onto supported nitrocellulose filters (11) . Gel-purified fragments used as probes included the 1.2-kb G418-resistance cassette (Cia I digest) from the pGD vector, a 2.5-kb c-abl-specific fragment (HincIl digest) from pRS-2 (12), and a 2-kb mouse /3-globin (HindIII-BamHI) fragment excised from plasmid pUCMImaj, which contains the mouse /8-globin major locus described by Konkel et al. (13) and was provided by M. Baron (Harvard University). Also used was a mixture of Zfxand Zfy-specific DNA fragments [(pDP1055 and pDP1193, provided by E. M. Simpson and D. C. Page (Whitehead Institute); (14) ] to determine the sex of origin of tumor cell lines. A probe containing the coding region of the murine erythropoietin receptor (15) 
RESULTS
Histopathology. Twenty-two lethally irradiated animals were injected with bone marrow infected by v-abl-containing virus. All animals were deemed reconstituted insofar as they survived longer than 2 weeks after irradiation, but all died within 16 weeks of transplant. Data is shown for those mice sacrificed when moribund; the remainder were not well enough preserved to allow complete autopsy. Each recipient mouse examined had developed disease of multiple hematopoietic lineages. Table 1 shows the results of peripheral blood studies and the disease histology ascertained by hematoxylin/eosin sections in individual animals. The disease latency of 4-10 weeks is comparable to that reported in previous studies using v-abl in a similar protocol (4) and to that observed for the bcr-ablassociated CML-like disease reported by Daley et al. (8) . The mice carrying cells infected with v-abl under these conditions developed an abnormal peripheral blood granulocytosis suggestive of, but not by itselfdiagnostic of, a CML-like syndrome.
Beyond these similarities, significant differences between the diseases caused by v-abl and bcr-abl were evident. (i) The average white blood cell counts in our v-abl mice were substantially lower than in those mice that received bcr-abl virus by a similar protocol: the maximum of 61,000 reported here is nearly an order ofmagnitude lower than the maximum recorded in mice receiving marrow infected by bcr-abl and is comparable to the number reported by Kelliher et al. (4) in similar studies. (it) The granulocytes of v-abl-infected mice were almost entirely mature cells, whereas animals with a true CML-like syndrome exhibited both mature and immature cells in their peripheral blood. (iii) The marked splenomegaly occurring in mice that have received p210-expressing marrow was not present in the v-abl-infected mice. Mean spleen weights of0.60 ± 0.17 g noted in our previous study of bcr-abl-infected mice are significantly greater than the 0.30 ± 0.03 g observed here; spleen weights for untreated BALB/c mice of this age are =0.1 g. (iv) Hematoxylin/eosin staining of spleen sections from v-abl-infected animals revealed splenic disease very different from that occurring in bcr-abl- locytes (Fig. 2) ; hybridization with a c-abl probe showed only endogenous c-abl sequences (data not shown).
Cells from other tissues, however, contained v-abl at a readily detectable copy number. A c-abl probe was hybridized to DNA from liver, spleen, and lymph node or tumor tissue in representative mice. EcoRI cleaved the integrated provirus in the neo cassette, yielding fragments the sizes of which varied depending upon integration site. Xba I cuts within the long terminal repeat sequences of the integrated provirus, giving a fragment independent in length of the integration site. In each case, primary lymphoid or macrophage tumor tissue contained a limited number (1-3) of integrated proviruses detected either by neo or abl probes (Fig. 3) . These proviral genomes were present at significant copy number (-0.5-1.0 copy per genome, as estimated from the ratio of intensity of integrated provirus to endogenous c-abl bands) in the liver, spleen, or tumor tissue of all animals tested. These data established that v-abl was present in the malignant cells in recipient animals.
Cell Lines. Tumor cells and bone marrow were harvested from each autopsied animal and cultured. Cell lines were established from seven independent tumors. These lines were analyzed by Wright-Giemsa staining, antibody staining for selected lineage markers, and Southern blotting to assay provirus (c-abl and neo probes), immunoglobulin heavychain gene configuration (JH probe), and origin (male donor or female recipient). We also used Northern (RNA) blotting to determine lineage and immunoprecipitation with anti-abl sera to establish the presence of p160 in the cell lines. Results of these analyses are shown in Table 2 homologous to P3-globin, the erythropoietin receptor, or to Rag-i [a gene central to variable/diversity/joining region recombination in pre-B cells (16) ]. However, these cells exhibited JH rearrangements at both alleles (Fig. 4) . In four of five B220' lines, the mRNA for Rag-1 was readily detected, and both JH alleles had undergone rearrangement, similar to the pattern predicted from previously characterized A-MuLV-transformed lines (17) . All cells contained either one or two copies of provirus detected by hybridization to neo-specific probes, were of donor (male) origin by hybridization to Zfx/Zfy probes, and contained the characteristic v-abl (p160) gene product, as assayed by immunoprecipitation and autophosphorylation reactions (18) .
DISCUSSION
On the basis of these and previous results, v-abl and bcr-abl apparently differ in the spectrum of hematopoietic disease they induce. The bcr-abl gene product likely initiates CML in humans. A CML-like syndrome has been seen in nearly half of the diseased mice transplanted in our laboratory with bone-marrow cells that contain a retrovirally transduced bcr-abl cDNA (8) . This syndrome is characterized by massive splenic enlargement with total obliteration of splenic architecture by mature granulocytes. These animals also exhibit white blood cell counts similar to those in the human disease. Notably, the provirus coding for p210 is present at single-copy levels in these granulocytes.
v-abl causes a disease that differs by several criteria. a v-abl-containing virus also exhibit a more modest granulocytosis in peripheral blood and do not harbor the provirus at significant copy number in their granulocytes. In those tissues where provirus is detectable, histology confirms that the number ofgranulocytes is not sufficient to account for the observed signal. Given these findings, we believe that the granulocytes in these mice are not descended from the malignant clone and are probably not malignant cells. A potential explanation for this phenomenon is suggested by the molecular analysis of Elefanty et al. (7), who found that a number of their p210-transformed macrophage cell lines produced biologically active granulocyte/macrophage colony-stimulating factor. Elaboration of a granulocytestimulating factor by the frequently observed macrophage nodules in our v-abl-infected mice might well account for the peripheral blood picture described above.
Still, significant similarities in the diseases caused by v-abl and bcr-abl are notable. As described in both our work above and in previous studies by Kelliher et masses readily give rise to cell lines that produce p160 and that exhibit cell-surface markers characteristic of lymphoid or myeloid lineages. Other early cells may be involved as well, as evidenced by our isolation of one lineage-negative cell line. The presence of nests of erythroid proliferation on the histologic sections suggests, but does not prove, that involvement of the erythroid lineage is possible in this host/vector system using v-abl.
The phenotype of disease in animals infected by viruses containing activated c-abl variants is determined by a number of factors. One is the route of administration. Demonstration of a pre-B cell tumor phenotype in animals receiving A-MuLV i.v. or intraperitoneally was followed by the demonstration that the virus could, after intrathymic injection, transform T cells, even in mouse strains previously thought resistant to Abelson virus transformation (19, 20) . As we have used identical infection protocols for bcr-abl and v-abl here, other explanations for the difference in phenotype must be sought. A second possibility is that infection of different target-cell populations occurred. The lymphoid precursor cell that A-MuLV transforms to yield pre-B cell tumors has been relatively well characterized (21) . Hematopoietic stem cells are apparently involved in human disease (22) , while preliminary studies (G.Q.D., R.A.V., and D.B., unpublished work) suggest that the murine CML target is a pluripotent cell also. Although the data above do not clearly demonstrate stem-cell infection, our isolation of Mac-i-positive cell lines that have rearranged both immunoglobulin ,u alleles suggests transfer of v-abl to an early cell capable of differentiating along both myeloid and lymphoid pathways. As we have used viruses of similar titer under identical infection conditions in both our bcr-abl and v-abl studies, it seems likely that we are initially introducing these activated abl genes into similar populations of cells.
A third potentially important variable in determination of the phenotype of disease is the nature of the retroviral vector system used to introduce activated abl variants into marrow cells. Although the vector used in our v-abl and bcr-abl experiments is identical, helper virus was in the producer cell population used in the v-abl experiments but not in the previous study. This may account, at least in part, for the frequency of lymphoid disease observed in mice whose marrow is infected with v-abl. In contrast to the helper-free system, infection by v-abl of an expanding pool of maturing pre-B cell progenitors could occur after transplantation of marrow into the lethally irradiated recipient animals. It is difficult, however, to see how this could restrict the ability of v-abl to transform the target-cell population that could give rise to a CML-like syndrome. One might argue that the presence of helper virus could accelerate disease onset in other lineages, such that recipient animals would die of different malignancies before exhibiting the CML phenotype. However, the latency of CML-like disease in mice receiving bcr-abl-infected marrow was sufficiently short that one would expect to see at least some animals with that disease if v-abl behaved identically with respect to transformation of a myeloid progenitor cell population. Yet another argument against the importance of helper virus comes from the results of Chung et al. (5) , who used a helper-free v-abl producer cell line. They also observe malignant macrophage-like and lymphoid disease but do not document massive expansion of the mature granulocyte compartment or the presence of provirus in this lineage in vivo.
If these explanations do not account for the difference in diseases induced by bcr-abl and v-abl, structural differences between the two proteins are a potential explanation. Several structural features determining the transforming properties of activated c-abl variants have been previously defined. Motifs necessary for transformation in all cell types include the SH2 region and kinase domains, whereas the presence of a myristoylation site near the N terminus of activated proteins appears required for fibroblast transformation (23, 24) . Although deletion of regions such as SH3 can activate transforming ability, the most common naturally occurring mutations involve appending additional sequence information to the N terminus of a partly deleted gene product. These include addition of retroviral gag sequences (in A-MuLV or Hardy Zuckerman feline sarcoma virus) or bcr sequences (in the Philadelphia translocation) to a partially deleted c-abl molecule. The role of these additions remains poorly defined, but several mechanisms can be envisioned. Steric hindrance of the interaction between regulatory regions normally present in c-abl and other molecules may occur. The SH3 domain appears to function as a negative regulator oftransformation, whereas the SH2 domain recently has been shown to interact specifically with several proteins that have undergone tyrosine phosphorylation in cells transformed by activated abl variants (25) . Another mechanism might involve acquisition of an additional functionality by the abl protein. gag sequences, in part, determine protein stability in lymphoid cells (26) and subcellular distribution through provision of a myristoylation site (27) . Although no enzymatic activity has been proposed for gag, a serine/threonine kinase activity has previously been suggested for the bcr gene product (28) . Further investigation of the structural properties of these abl variants will clearly be necessary to identify regions responsible for the specificity of transformation they exhibit.
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